Monthly Prescribing Reference

FDA Expands Use of RELiZORB to Include Children

In the study, authors measured plasma omega-3 fatty acid concentrations as markers of fat absorption. Safety and tolerability were assessed by documentation of gastrointestinal (GI) symptoms. Alcresta ...
Monthly Prescribing Reference

RELiZORB Cleared for Younger Patients Experiencing Fat Malabsorption

RELiZORB RELiZORB is a digestive enzyme cartridge designed to hydrolyze fats contained in enteral formulas. The Food and Drug Administration (FDA) has cleared RELiZORB (immobilized lipase) cartridge ...
Yahoo Finance

Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Critical Care Patients at Inova Fairfax Medical Campus

WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...
Yahoo Finance

Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients 1 Year of Age and Older

WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced ...
Business Wire

Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid ...

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. announced the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB. RELiZORB ...
Medindia

Alcresta Therapeutics Announces FDA Clearance for the Next-Generation RELiZORB® Digestive Enzyme Cartridge

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. "Tube-fed patients have a wide range of enteral nutrition ...
Pharmabiz

Alcresta Therapeutics announces MGH enrols first patient in clinical trial evaluating use of RELiZORB in pancreatitis patients

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced that Massachusetts General Hospital (MGH) has enrolled ...
Business Wire

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB ®

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a ...
Morningstar

Alcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®

WALTHAM, Mass., Jan. 23, 2026 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced the ...
KRQE Blogs

Alcresta Therapeutics Announces FDA Clearance for the Next-Generation RELiZORB® Digestive Enzyme Cartridge

Next-generation RELiZORB technology expands device utility to support more patients including many living with SBS and other rare diseases. WALTHAM, Mass., Dec. 21, 2023 /PRNewswire/ -- Alcresta ...
Pharmabiz

Alcresta announces publication of real-world evidence showing improvements in growth for children ages 1 to 5 years old with use of RELiZORB

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced the publication of real-world evidence results of ...